A rapid review of pre-exposure prophylaxis for HIV in the Asia-Pacific region: recommendations for scale up and future directions.


Journal

Sexual health
ISSN: 1449-8987
Titre abrégé: Sex Health
Pays: Australia
ID NLM: 101242667

Informations de publication

Date de publication:
03 2021
Historique:
received: 09 04 2020
accepted: 13 01 2021
pubmed: 27 2 2021
medline: 15 12 2021
entrez: 26 2 2021
Statut: ppublish

Résumé

Decline in new HIV infections in the Asia-Pacific region (APAC) continues to be slow, emphasising the importance of scaling up new HIV prevention strategies, such as pre-exposure prophylaxis (PrEP). To help inform PrEP rollout in APAC, we conducted a rapid review of published literature on PubMed from 2015 to 2020, to assess feasibility, implementation strategies, cost-effectiveness, and availability of national policies and guidelines; for the latter, we also did an expanded Internet search. This review focussed on nine countries contributing >95% of new infections in this region. A total of 36 PrEP-related studies conducted among men who have sex with men, female sex workers, and transgender women were included, of which 29 were quantitative, six were qualitative and one was a mixed-method study. Most of the studies have addressed the availability and acceptability of PrEP, whereas cost-effectiveness of any approach was assessed by limited studies. Limited published information was available about national PrEP policies and guidelines; of the selected nine countries, five have adopted the recommended World Health Organization PrEP policy of which four have integrated it in their national HIV response. HIV risk perception concerns about safety, side-effects, stigma, and affordability were major challenges to PrEP acceptance. Community-based implementation has the potential to address these. Limited evidence suggested merging PrEP implementation with ongoing targeted intervention and treatment programs could be a cost-effective approach. To stem the epidemic, newer effective prevention strategies, like PrEP, should be urgently adopted within the context of combination HIV prevention approaches.

Identifiants

pubmed: 33632382
pii: SH20058
doi: 10.1071/SH20058
doi:

Substances chimiques

Anti-HIV Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

31-40

Subventions

Organisme : World Health Organization
ID : 001
Pays : International

Auteurs

Partha Haldar (P)

All India Institute of Medical Sciences, Centre for Community Medicine, New Delhi, India.

Sushena Reza-Paul (S)

University of Manitoba, Institute for Global Public Health, Rady Faculty of Health Sciences, Winnipeg, Manitoba, Canada; and Corresponding author. Email: sushenar@gmail.com.

Roy Arokiam Daniel (RA)

All India Institute of Medical Sciences, Centre for Community Medicine, New Delhi, India.

Lisa Lazarus (L)

University of Manitoba, Institute for Global Public Health, Rady Faculty of Health Sciences, Winnipeg, Manitoba, Canada.

Bharat Bhushan Rewari (BB)

World Health Organization Regional Office for South-East Asia, New Delhi, Delhi, India.

Robert Lorway (R)

University of Manitoba, Institute for Global Public Health, Rady Faculty of Health Sciences, Winnipeg, Manitoba, Canada.

R Steen (R)

Erasmus Medical Center, Department of Public Health, Rotterdam, Zuid-Holland, Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH